Methods for inhibiting lymphotoxin beta receptor signalling

A method for inhibiting a Th1 cell-mediated immune response in an animal comprising the step of administering a pharmaceutical composition which comprises an effective amount of a LT-β-R blocking agent and a pharmaceutically effective carrier.

A pharmaceutical composition comprising a therapeutically effective amount of a LT-β-R blocking agent and a pharmaceutically acceptable carrier.

A method for selecting a LT-β-R blocking agent comprising the steps of:

• a) culturing tumor cells in the presence of an effective amount of at least one LT-β-R activating agent and a putative LT-β-R blocking agent;
• and
• b) determining whether the putative LT-β-R blocking agent decreases the anti-tumor activity of the LT-β-R activating agent.

A method for inhibiting LT-β-R signalling without inhibiting TNF-R signalling comprising the step of administering to a subject an effective amount of a LT-β-R blocking agent.

A method of treating inflammatory bowel syndrome comprising administering a therapeutically effective amount of an LT-β-R fusion protein.